IPH
XPAR
Market cap101mUSD
Nov 20, Last price
0.83EUR
1D
-8.51%
1Q
-56.65%
Jan 2017
-94.33%
IPO
-82.64%
Name
Innate Pharma SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Key people
Jonathan Dickinson
Chairman of the Executive Board, Chief Executive Officer, Member of the Leadership Team · since 2024
Frederic Lombard
Chief Financial Officer, Member of the Leadership Team · since 2024
Yannis Morel
Chief Operating Officer, Executive Vice President, Member of the Executive Board, Member of the Leadership Team · since 2024
Executive Vice President, Member of the Executive Board, Chief Medical Officer, Member of the Leadership Team · since 2024
Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team · since 2024
Odile Laurent
Vice President - Human Resources, Member of the Executive Committee · since 2017
Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team · since 2024
Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Executive Committee · since 2019
Arvind Sood
Executive Vice President, President of US Operations, Member of the Executive Board · since 2024
Eric Vivier
Senior Vice President, Chief Scientific Officer, Guest Member of the Executive Committee · since 2018
Claire De Saint-blanquat
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team · since 2024
Chairwoman of the Board of Directors · since 2025
Independent Member of the Supervisory Board · since 2022
Independent Member of the Supervisory Board · since 2017
Veronique Chabernaud
Independent Member of the Supervisory Board · since 2015
Pascale Boissel
Independent Member of the Supervisory Board · since 2020
Gilles Brisson
Member of the Supervisory Board · since 2024
Member of the Supervisory Board, Representative of Bpifrance Participations · since 2021
Headquarters & legal address
117 AVENUE DE LUMINY
MARSEILLE 13009
FR
MARSEILLE 13009
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||